This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.theguardian.com/business/2023/jun/01/dr-martens-profits-us-supply-problems-la-warehouse

The article has changed 4 times. There is an RSS feed of changes available.

Version 0 Version 1
Dr Martens profits tumble amid US supply problems Sales of Dr Martens sandals and shoes soar as boots slide
(about 8 hours later)
British bootmaker says it faces ‘challenging’ US market and rising costs at LA warehouse British brand’s profits tumble after string of errors in US operation hits sales
Dr Martens said it has struggled to sell its chunky lace-up boots in the US and admitted attempts to correct “mistakes” in its American supply chain had triggered a slide in its annual profits. Dr Martens has revealed a slide in profits as sales of its key product – boots – fell 10% last year after the British brand made a string of errors at its US business and pulled back distribution in Latin America and China.
The British bootmaker said it had faced falling demand in the US, blaming what it called a “challenging consumer environment”, as shoppers reined in their spending in the face of high inflation. The footwear maker said sales of its chunky sandals and shoes had risen by about 50% to become almost a third of total sales, but boot sales had suffered, particularly in America, after it focused marketing on its other products and struggled with problems at a warehouse in Los Angeles.
The company also blamed what it called a “challenging consumer environment” for a fall in demand in the US as shoppers reined in their spending in the face of high inflation.
First created in 1945 by a young German army doctor, Klaus Märtens, who designed an air-cushioned sole to help his recovery from a broken foot, the boots were first introduced to Britain in 1960 by a Northamptonshire footwear maker.First created in 1945 by a young German army doctor, Klaus Märtens, who designed an air-cushioned sole to help his recovery from a broken foot, the boots were first introduced to Britain in 1960 by a Northamptonshire footwear maker.
Their sturdy design meant they were initially adopted by postal delivery workers and factory staff, but the classic eight-holed 1460 boots also quickly found favour with punks. Their sturdy design meant the boots were initially adopted by postal delivery workers and factory staff, but the classic eight-holed 1460 boots also quickly found favour with punks.
In the past 12 months, the footwear group has been battling growing costs of £15m at its Los Angeles distribution centre, which opened last year. Kenny Wilson, the Dr Martens chief executive, said the decline in sales of boots last year was not down to the footwear falling out of fashion.
This caused its annual profit before tax to tumble by 26% to £159m, as a result of slower sales growth, investment in new stores, marketing and staff, as well as rectifying the US warehouse problems. He said sales had risen 12% in the UK, driven by boots, and the brand had enjoyed strong sales across Europe and Japan, another important market. Wilson added that if planned changes to distribution agreements in China and Latin America were excluded then global boot sales were up 2%.
Dr Martens blamed “operational mistakes” including the move to its LA warehouse for some of its problems across the Atlantic, including supply chain bottlenecks that forced it to open temporary US warehouses in late 2022 to deal with stock. In the past 12 months, the footwear group has been battling growing costs of £15m after a string of “operational mistakes” at its Los Angeles distribution centre, which opened last year. The group was forced to open temporary US warehouses in late 2022 after it bought too much stock and suffered supply chain bottlenecks.
Kenny Wilson, the Dr Martens chief executive, said the company had “undertaken detailed reviews to understand” why it had experienced problems in the US, the brand’s largest country by revenues. The costs of rectifying the US problems alongside slower than hoped for sales growth, investment in new stores, marketing and staff led to a 26% tumble in annual profit before tax to to £159m in the year to 31 March. Annual sales reached £1bn for the first time, a 10% increase on a year earlier.
“We are fixing the issues in America, including a significant strengthening of the team there, and returning America to good growth is our number one operational priority,” he said. Wilson said the company had “undertaken detailed reviews to understand” why it had experienced problems in the US, the brand’s largest country by revenues.
However, he said profit margins were likely to be lower than previously hoped in the year ahead as the company continued to invest in its infrastructure.
The news sent Dr Martens shares tumbling by as much as 14% during morning trading on Thursday, before recovering some of their losses.The news sent Dr Martens shares tumbling by as much as 14% during morning trading on Thursday, before recovering some of their losses.
The company first floated two-and-a-half years ago, in January 2021, debuting at 370p a share, giving it a valuation of £3.7bn. They are now trading at about 140p, more than 60% lower than their opening price, and have almost halved over the past year, amid profit warnings.
The bootmaker’s underlying annual profits slid 7% to £245m, below the £260m forecast it made last November after two profit warnings in the space of a few months.
Sales of its boots were healthier in Europe, the Middle East and Africa, as well as its key market of Japan, the company’s third largest.
Sign up to Business TodaySign up to Business Today
Get set for the working day – we'll point you to all the business news and analysis you need every morningGet set for the working day – we'll point you to all the business news and analysis you need every morning
after newsletter promotionafter newsletter promotion
Annual sales reached £1bn for the first time during the 12 months to the end of March, a 10% increase on a year earlier. The company first floated two-and-a-half years ago, in January 2021, debuting at 370p a share, giving it a valuation of £3.7bn. They are now trading at about 140p, more than 60% lower than their opening price, and have almost halved over the past year, amid profit warnings.
The bootmaker’s underlying annual profits slid 7% to £245m, below the £260m forecast it made last November after two profit warnings in the space of a few months.
The company has brought in price rises for the past two years, announcing a 6% increase last November to cover higher costs of energy, labour and the leather and bouncy soles used to make its footwear.The company has brought in price rises for the past two years, announcing a 6% increase last November to cover higher costs of energy, labour and the leather and bouncy soles used to make its footwear.
The latest price rise, which will come into force this autumn, will add about £10 to the cost of its classic boot, from £159 now. The latest price rise, which will come into force in July , will add about £10 to the cost of its classic boot, from £159 now.
Despite the high price for its footwear, Dr Martens is well placed at a time of squeezed consumer finances, said Julie Palmer, a partner at the insolvency firm Begbies Traynor. Wilson said that he anticipated Dr Martens’ cost inflation to continue into next year but the rate had slowed to 2% for spring/summer next year, as the price of leather and shipping had reduced.
“Its big-selling, big-soled boots and shoes may be expensive, but are built to last and what shoppers increasingly wanting durability as well as fashion are seeking out,” she said.
“Supply chain costs are also on the rise but management say they will be able to cover these with price increases, something consumers are likely to absorb because of the products’ premium price tag.”